Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed.

Feldmann M., Maini RN., Woody JN., Holgate ST., Winter G., Rowland M., Richards D., Hussell T.

DOI

10.1016/S0140-6736(20)30858-8

Type

Journal article

Journal

Lancet

Publication Date

02/05/2020

Volume

395

Pages

1407 - 1409

Keywords

Antibodies, Betacoronavirus, Clinical Trials as Topic, Coronavirus Infections, Cytokines, Humans, Inflammation, Pandemics, Pneumonia, Viral, Tumor Necrosis Factor-alpha

Permalink Original publication